ORTHOCELL LIMITED — Capital/Financing Update 2018

Oct 10, 2018

==> picture [594 x 111] intentionally omitted <==

Orthocell receives A$2.5m R&D tax incentive refund

Perth, Australia; 11 October 2018 : Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell”, or the “Company”) is pleased to announce that it has received a Research and Development (R&D) Tax Incentive refund of A$2,528,159 for the financial year 2017/2018.

Orthocell Managing Director Paul Anderson said: “The receipt of the R&D Tax Incentive refund strengthens our balance sheet, supports our current CelGro® market entry plans into key EU markets and enables progression of key R&D activities. We are making excellent progress in driving sales of CelGro® for dental bone repair and continue to receive positive feedback on the superior quality and handling characteristics from customers and end users.”

The R&D Tax Incentive is an Australian Government program to support Australian companies to undertake R&D activities in Australia, under which eligible companies can receive cash rebates of up to 43.5% of eligible expenditure on R&D activities.

For more information, please contact:

General enquiries	Investor enquiries	Media enquiries
Paul Anderson	Joel Seah	Haley Chartres
Orthocell Limited	Vesparum Capital	Hales2 Communications
Managing Director
P: +61 8 9360 2888	P: +61 3 8582 4800	P: +61 423 139 163
E: paulanderson@orthocell.com.au	E: orthocell@vesparum.com	E: haley@h-squared.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell’s portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for first approval in the US.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter @Orthocellltd and Linkedin www.linkedin.com/company/orthocell-ltd

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au